Page 23 - ANZCP Gazette AUG 2023

2. The appropriate use of cell salvage
The use of cell salvage is an STS Class 1 level A, and a Class 2A level A recommendation. It also features in the National Blood Authority Patient Blood Management recommendations #15 and #20, Grade C. Yet, how widely is it utilised across local sites? Figure 4 shows
the collective rates of cell salvage across the whole collaboration over time. The blue indicates cases where no cell salvage was used. It is clear cell salvage rates are increasing and is now used 63 % of cases across all cases across all sites. Figure 5 indicates a single site cell saver usage over time, and the model of device used. This reported graph may indicate an opportunity for this site to build their use of cell salvage going forward. Figure 6 displays a snapshot for cell salvage use across all sites for 2021. There is quite a wide variation in practise. Participating sites use the information contained in these graphs to evaluate their own practises relative to other sites and evaluate opportunities to maximise the use of call salvage for their centre.
Fig 4 Multisite
Fig 5 Single Site
3. The use of retrograde autologous priming (RAP)
The use of RAP is an STS Class 1 level B-R recommendation. The use of RAP has been increasing across the collaborate, Figure 7. Figure 8 shows this single site changed its practise in 2015 to adopt RAP which it still uses in almost 80% of cases. Yet, there
is variation in the adoption of RAP in 2021 across participating sites (Fig 9a) and variation in the RAP volume (Fig 9b).
Fig 7 Multisite
Fig 8 Single site
Fig 9a Multisite use of RAP 2021
Fig 6 multisite 2021
SEPTEMBER 2023 3SCTS SPECIAL EDITION | www.anzcp.org 21